2. GPCR/G Protein
  3. GLP Receptor
  4. Tirzepatide hydrochloride

Tirzepatide hydrochloride  (Synonyms: LY3298176 hydrochloride)

Cat. No.: HY-P1731B Purity: 99.96%
COA Handling Instructions

Molarity Calculator

Tirzepatide hydrochloride (LY3298176 hydrochloride) is a glucose-dependent insulin nutritive polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist. Tirzepatide hydrochloride has neuroprotective effects and can be used in the study of type 2 diabetes, diabetes-related neuropathy and obesity.

For research use only. We do not sell to patients.

Tirzepatide hydrochloride Chemical Structure

Tirzepatide hydrochloride Chemical Structure

Size Price Stock Quantity
1 mg USD 320 In-stock
5 mg USD 850 In-stock
10 mg USD 1380 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of Tirzepatide hydrochloride:

Tirzepatide hydrochloride Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Tirzepatide hydrochloride (LY3298176 hydrochloride) is a glucose-dependent insulin nutritive polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist. Tirzepatide hydrochloride has neuroprotective effects and can be used in the study of type 2 diabetes, diabetes-related neuropathy and obesity[1][2][3].

In Vitro

Tirzepatide hydrochloride (0-0.4 μM, 7 days) is used to improve the neurodegeneration of SHSY5Y human neuroblastoma cells induced by high glucose and to overcome neuronal insulin resistance[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Tirzepatide hydrochloride Related Antibodies

Western Blot Analysis[1]

Cell Line: SHSY5Y
Concentration: 0-0.4 μM
Incubation Time: 7 days
Result: Upregulated the mRNA expression and protein levels of both CREB and BDNF.
Increased the Bcl-2 and decreased BAX protein levels.
Increased the pAkt, MAP2, GAP43, and AGBL4 protein levels.
Increased GLUT4 and SORBS1 protein levels.
In Vivo

Tirzepatide hydrochloride (10 nmol/kg, subcutaneous injection) can inhibit colon cancer tumor growth in dietary-obese mice[2].
Tirzepatide hydrochloride (1.35 mg/kg, intraperitoneal injection, once per week) improves spatial learning and memory impairment by modulating abnormal insulin resistance and inflammatory response in diabetic rats[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Diet-induced obese (DIO) mice [2]
Dosage: 10 nmol/kg
Administration: s.c.
Result: Reduced body weight and food consumption.
Reduced glucose, insulin, leptin, and c-peptide levels.
Animal Model: MC38 colon cancer mice model[2]
Dosage: 10 nM/kg
Administration: s.c.
Result: Reduced tumor volumes.
Clinical Trial
Molecular Weight

4813.45 (free base)

Formula

C225H348N48O68.xHCl
Appearance

Solid

Color

White to off-white

Sequence

Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{Aib}-Leu-Asp-Lys-Ile-Ala-Gln-{C20 diacid-gamma-Glu-(AEEA)2-Lys}-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Sequence Shortening

Y-{Aib}-EGTFTSDYSI-{Aib}-LDKIAQ-{C20 diacid-gamma-Glu-(AEEA)2-Lys}-AFVQWLIAGGPSSGAPPPS-NH2
SMILES

OC[C@H](NC([C@H]1N(CCC1)C([C@H]2N(CCC2)C([C@H]3N(CCC3)C([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@H]4N(CCC4)C(CNC(CNC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(C(C)(NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC(C(C)(NC([C@@H](N)CC5=CC=C(C=C5)O)=O)C)=O)CCC(O)=O)=O)=O)[C@@H](C)O)=O)CC6=CC=CC=C6)=O)[C@@H](C)O)=O)CO)=O)CC(O)=O)=O)CC7=CC=C(C=C7)O)=O)CO)=O)[C@H](CC)C)=O)C)=O)CC(C)C)=O)CC(O)=O)=O)CCCCN)=O)[C@H](CC)C)=O)C)=O)CCC(N)=O)=O)CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@H](NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)C(O)=O)=O)=O)=O)=O)C)=O)CC8=CC=CC=C8)=O)C(C)C)=O)CCC(N)=O)=O)CC9=CNC%10=C9C=CC=C%10)=O)CC(C)C)=O)[C@H](CC)C)=O)C)=O)=O)=O)=O)CO)=O)CO)=O)=O)C)=O)=O)=O)=O)C(N)=O.[H]Cl.[x]
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility
In Vitro: 

DMSO : 50 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 5 mg/mL (Infinity mM); Clear solution

    This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 5 mg/mL (Infinity mM); Clear solution

    This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.96%

COA (276 KB) RP-HPLC (246 KB) LCMS (92 KB) Elemental Analysis Report (99 KB)

Handling Instructions (2659 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Tirzepatide hydrochloride Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

TirzepatideLY3298176LY 3298176LY-3298176GLP ReceptorType 2 diabetesneuropathyAlzheimer's diseaseobesityInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Tirzepatide hydrochloride
Cat. No.:
HY-P1731B
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.